ATE518853T1 - Verbindungen zur behandlung entzündlicher erkrankungen - Google Patents

Verbindungen zur behandlung entzündlicher erkrankungen

Info

Publication number: ATE518853T1
Authority: AT; Austria
Prior art keywords: compounds; treatment; inflammatory diseases; diseases; mmps
Prior art date: 2005-08-12

Application number

AT06789659T

Other languages

English (en)

Inventor

Zhaoning Zhu

Robert Mazzola

Wensheng Yu

Joseph Kozlowski

Original Assignee

Schering Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2005-08-12

Filing date

2006-08-10

Publication date

2011-08-15

2006-08-10 Application filed by Schering Corp filed Critical Schering Corp

2011-08-15 Application granted granted Critical

2011-08-15 Publication of ATE518853T1 publication Critical patent/ATE518853T1/de

Links

150000001875 compounds Chemical class 0.000 title abstract 3
208000027866 inflammatory disease Diseases 0.000 title 1
MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 abstract 1
102000002274 Matrix Metalloproteinases Human genes 0.000 abstract 1
108010000684 Matrix Metalloproteinases Proteins 0.000 abstract 1
108060008682 Tumor Necrosis Factor Proteins 0.000 abstract 1
102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 abstract 1
201000010099 disease Diseases 0.000 abstract 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
230000001404 mediated effect Effects 0.000 abstract 1
150000003839 salts Chemical class 0.000 abstract 1
239000012453 solvate Substances 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Immunology (AREA)
Physical Education & Sports Medicine (AREA)
Rheumatology (AREA)
Orthopedic Medicine & Surgery (AREA)
Cardiology (AREA)
Pulmonology (AREA)
Tropical Medicine & Parasitology (AREA)
Neurosurgery (AREA)
Oncology (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Ophthalmology & Optometry (AREA)
Heart & Thoracic Surgery (AREA)
Diabetes (AREA)
Virology (AREA)
Communicable Diseases (AREA)
Dermatology (AREA)
Addiction (AREA)
Hematology (AREA)
Psychiatry (AREA)
Urology & Nephrology (AREA)
AIDS & HIV (AREA)
Vascular Medicine (AREA)
Molecular Biology (AREA)
Gastroenterology & Hepatology (AREA)

AT06789659T 2005-08-12 2006-08-10 Verbindungen zur behandlung entzündlicher erkrankungen ATE518853T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US70765305P	2005-08-12	2005-08-12
PCT/US2006/031151 WO2007021803A1 (en)	2005-08-12	2006-08-10	Compounds for the treatment of inflammatory disorders

Publications (1)

Publication Number	Publication Date
ATE518853T1 true ATE518853T1 (de)	2011-08-15

Family

ID=37560931

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT06789659T ATE518853T1 (de)	2005-08-12	2006-08-10	Verbindungen zur behandlung entzündlicher erkrankungen

Country Status (8)

Country	Link
US (1)	US7879997B2 (de)
EP (1)	EP1948638B1 (de)
JP (1)	JP2009504666A (de)
CN (1)	CN101282962A (de)
AT (1)	ATE518853T1 (de)
CA (1)	CA2618679A1 (de)
MX (1)	MX2008002073A (de)
WO (1)	WO2007021803A1 (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2012005229A1 (ja)	2010-07-08	2012-01-12	科研製薬株式会社	Ｎ－ヒドロキシホルムアミド誘導体およびそれを含有する医薬
CN103917529B (zh)	2011-11-11	2016-08-17	辉瑞大药厂	2-硫代嘧啶酮类
AU2016257179A1 (en)	2015-05-05	2017-11-02	Pfizer Inc.	2-thiopyrimidinones

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4166452A (en)	1976-05-03	1979-09-04	Generales Constantine D J Jr	Apparatus for testing human responses to stimuli
US4256108A (en)	1977-04-07	1981-03-17	Alza Corporation	Microporous-semipermeable laminated osmotic system
US4265874A (en)	1980-04-25	1981-05-05	Alza Corporation	Method of delivering drug with aid of effervescent activity generated in environment of use
US5318964A (en)	1992-06-11	1994-06-07	Hoffmann-La Roche Inc.	Hydroxamic derivatives and pharmaceutical compositions
GB9215665D0 (en)	1992-07-23	1992-09-09	British Bio Technology	Compounds
AU4444393A (en) *	1992-09-01	1994-03-10	Zeneca Limited	Pyrrolidine derivatives
GB9307956D0 (en)	1993-04-17	1993-06-02	Walls Alan J	Hydroxamic acid derivatives
GB9320660D0 (en)	1993-10-07	1993-11-24	British Bio Technology	Inhibition of cytokine production
EP1099690A4 (de)	1998-07-23	2001-10-17	Shionogi & Co	Monozyklische beta-lactamverbindungen und chymase inhibitoren, die diese enthalten
EP1004578B1 (de)	1998-11-05	2004-02-25	Pfizer Products Inc.	5-Oxo-pyrrolidine-2-Carbonsäure-Hydroxamidderivate
EP1138680A1 (de)	2000-03-29	2001-10-04	Pfizer Products Inc.	Gem substituierte Sulfonylhydroxamsäuren mit MMP inhibierender Wirkung
CA2434205A1 (en) *	2001-01-11	2002-07-18	Dupont Pharmaceuticals Company	1,1-disubstituted cyclic inhibitors of matrix metalloprotease and tnf-.alpha.
PE20030701A1 (es)	2001-12-20	2003-08-21	Schering Corp	Compuestos para el tratamiento de trastornos inflamatorios
AU2002346729A1 (en)	2001-12-20	2003-07-09	Bristol-Myers Squibb Company	Barbituric acid derivatives as inhibitors of tnf-$g(a) converting enzyme (tace) and/or matrix metalloproteinases
AU2003259131A1 (en) *	2002-07-09	2004-01-23	Bristol-Myers Squibb Company	Substituted heterocyclic derivatives useful as antidiabetic and antiobesity agents and method
WO2005037826A1 (en) *	2003-10-17	2005-04-28	Incyte Corporation	Substituted cyclic hydroxamates as inhibitors of matrix metalloproteinases
WO2005077937A1 (en) *	2004-01-09	2005-08-25	Cadila Healthcare Limited	Substituted hydroxamic acid derivatives as tnf inhibitors
US7638513B2 (en)	2004-06-02	2009-12-29	Schering Corporation	Compounds for the treatment of inflammatory disorders
PE20060426A1 (es)	2004-06-02	2006-06-28	Schering Corp	DERIVADOS DE ACIDO TARTARICO COMO INHIBIDORES DE MMPs, ADAMs, TACE Y TNF-alfa
KR20070032787A (ko)	2004-07-16	2007-03-22	쉐링 코포레이션	염증 질환 치료용 히단토인 유도체
US7504424B2 (en)	2004-07-16	2009-03-17	Schering Corporation	Compounds for the treatment of inflammatory disorders
US7488745B2 (en)	2004-07-16	2009-02-10	Schering Corporation	Compounds for the treatment of inflammatory disorders
PE20071241A1 (es)	2006-01-17	2008-01-14	Schering Corp	Compuestos derivados de hidantoina para el tratamiento de trastornos inflamatorios
WO2008027466A1 (en)	2006-08-31	2008-03-06	Schering Corporation	Hydantoin derivatives useful as antibacterial agents

2006
- 2006-08-10 CN CNA200680037119XA patent/CN101282962A/zh active Pending
- 2006-08-10 WO PCT/US2006/031151 patent/WO2007021803A1/en not_active Ceased
- 2006-08-10 AT AT06789659T patent/ATE518853T1/de not_active IP Right Cessation
- 2006-08-10 EP EP06789659A patent/EP1948638B1/de active Active
- 2006-08-10 MX MX2008002073A patent/MX2008002073A/es unknown
- 2006-08-10 US US11/502,116 patent/US7879997B2/en active Active
- 2006-08-11 JP JP2008526185A patent/JP2009504666A/ja not_active Withdrawn
- 2006-08-11 CA CA002618679A patent/CA2618679A1/en not_active Abandoned

Also Published As

Publication number	Publication date
US20070191332A1 (en)	2007-08-16
US7879997B2 (en)	2011-02-01
WO2007021803A8 (en)	2008-01-10
EP1948638B1 (de)	2011-08-03
CN101282962A (zh)	2008-10-08
EP1948638A1 (de)	2008-07-30
WO2007021803A1 (en)	2007-02-22
CA2618679A1 (en)	2007-02-22
JP2009504666A (ja)	2009-02-05
MX2008002073A (es)	2008-04-16

Legal Events

Date	Code	Title	Description
2012-02-15	RER	Ceased as to paragraph 5 lit. 3 law introducing patent treaties

Publication	Publication Date	Title
TW200612911A (en)	2006-05-01	Compounds for the treatment of inflammatory disorders
EA200970581A1 (ru)	2009-12-30	Кристаллическое твёрдое основание разагилина
TW200736247A (en)	2007-10-01	Compounds for the treatment of inflammatory disorders
EA200800760A1 (ru)	2008-08-29	ПИРИДОПИРИМИДИНОНОВЫЕ ИНГИБИТОРЫ PI3Kα
EA201200669A1 (ru)	2012-11-30	ПИРИДОПИРИМИДИНОНОВЫЕ ИНГИБИТОРЫ PI3Kα
NO20083427L (no)	2008-10-14	Cystoksiske midler omfattende nye tomaymycinderivater og deres terapeutiske anvendelse
EA201100094A1 (ru)	2011-06-30	Тиадиазолилоксифениламидины и их применение в качестве фунгицидов
DK1853602T3 (da)	2010-09-20	Kemiske forbindelser
CY1108275T1 (el)	2014-02-12	Χημικες ενωσεις
EA201000642A1 (ru)	2010-10-29	2'-фтор-2'-дезокситетрагидроуридины в качестве ингибиторов цитидиндеаминазы
CR9347A (es)	2007-12-17	Derivados de pirimidina para el tratamiento de trastornos hiperproliferativos
EA201070247A1 (ru)	2010-06-30	Ингибиторы протеасом
MA29870B1 (fr)	2008-10-03	Nouveaux dérivés de 1-azabicycloalkyles dans le traitement de troubles psychotiques et neurodégénératifs
EA200500203A1 (ru)	2005-08-25	Новый способ синтеза и новая кристаллическая форма агомелатина и фармацевтические композиции, которые её содержат
JO3007B1 (ar)	2016-09-05	مركبات و تركيبات كمثبطات كيناز بروتين
NO20076371L (no)	2008-02-11	Fremgangsmate for fremstilling av fenoliske 4-bifenylylazetidin-2-oner
ATE554084T1 (de)	2012-05-15	N-hydroxyacrylamidverbindungen
NO20081050L (no)	2008-04-28	Kaspaseinhibitor-prodroger
NO20056192L (no)	2005-12-27	Kapaseinhibitorer og anvendelse derav
DE602004008959D1 (de)	2007-10-25	Benzoäbüä1,4üdioxepinderivate
MA32505B1 (fr)	2011-07-03	5-alcynyl-pyrimidines
ATE520651T1 (de)	2011-09-15	Substituierte phenylmethylbicyclocarbonsäureamidverbindungen
MA32943B1 (fr)	2012-01-02	Piperidine spiro pyrrolidione et piperidinone substituees, leur preparation et leur utilisation therapeutique
NO20073170L (no)	2007-06-22	Kaspaseinhibitorer og anvendelse derav
ATE517873T1 (de)	2011-08-15	6-oxo-1,6-dihydropyrimidin-2-yle bei der behandlung proliferativer krankheiten